-
Sector Analysis
NewUnited Kingdom (UK) Easter Market Analysis, Trends, Consumer Attitudes and Buying Dynamics, 2024 Update
United Kingdom (UK) Easter Market Report Overview The proportion of consumers agreeing that they did more Easter activities this year versus last year waned in 2024, as consumers opted for other activities during the long weekend. However, among those consumers with children, participation remained high, with over 62% of consumers with their youngest child being between 0-4 years of age agreeing that they did more Easter-related activities this year. As a result, retailers promoted various activities to encourage participation in...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Influenza [Strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (Quadrivalent, Split Virion) Vaccine in Seasonal Influenza
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Influenza [Strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (Quadrivalent, Split Virion) Vaccine in Seasonal Influenza report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical...
-
Product Insights
Likelihood of Approval Analysis for Female Contraception
Overview How likely is it that the drugs in Female Contraception will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Female Contraception Overview Contraception (birth control) prevents pregnancy by interfering with the...
-
Company Insights
NewDBV Technologies SA Pipeline Insight and Competitive Landscape, 2024
Empower your strategies with our DBV Technologies SA Pipeline Insight and Competitive Landscape, 2024 report and make more profitable business decisions. DBV Technologies SA (DBV Technologies) is a biopharmaceutical company. It develops self-administered and non-invasive therapies to treat food allergies and other immunological diseases. Its product pipeline includes Viaskin peanut, Viaskin milk and Viaskin EoE indicated for the treatment of related food allergies in children. It offers clinical trial services which comprises food allergy clinical trials, milk clinical trials, egg...
-
Product Insights
Likelihood of Approval Analysis for Food Allergy
Overview How likely is it that the drugs in Food Allergy will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Food Allergy Overview Food allergies are immune system reactions to certain proteins...
-
Sector Analysis
United Kingdom (UK) Easter Intentions and Consumer Spending Preferences, 2024 Update
United Kingdom (UK) Easter Market Report Overview More than 68% of consumers intend to purchase something for Easter in 2024. The intended participation in celebrating Easter diminishes with age, ranking highest among 16-24-year-old consumers. This 16-24-year-old age group is the most engaged purchaser, intending to purchase food & drink, gifts, cards & gift wraps, and other seasonal items for their loved ones. The UK Easter market research report offers a comprehensive insight into the dynamics and spending habits of UK...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Omalizumab in Food Allergy
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Omalizumab in Food Allergy Drug Details: Omalizumab (Xolair, Bolstran) is a recombinant DNA-derived humanized IgG1-kappa...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Omalizumab in Peanut Allergy
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Omalizumab in Peanut Allergy Drug Details: Omalizumab (Xolair, Bolstran) is a recombinant DNA-derived humanized IgG1-kappa...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Omalizumab in Milk Allergy
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Omalizumab in Milk Allergy Drug Details: Omalizumab (Xolair, Bolstran) is a recombinant DNA-derived humanized IgG1-kappa...
-
Product Insights
Focal Segmental Glomerulosclerosis (FSGS) – Drugs In Development, 2023
Global Markets Direct’s, ‘Focal Segmental Glomerulosclerosis (FSGS) - Drugs In Development, 2023’, provides an overview of the Focal Segmental Glomerulosclerosis (FSGS) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Focal Segmental Glomerulosclerosis (FSGS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...